PTC Therapeutics
PTCT
172 hedge funds and large institutions have $2.37B invested in PTC Therapeutics in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 71 increasing their positions, 56 reducing their positions, and 30 closing their positions.
249% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $3.38M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
29% more capital invested
Capital invested by funds: $1.84B → $2.37B (+$535M)
27% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 56
6.1% more ownership
Funds ownership: 107.7% → 113.8% (+6.1%)
4% less funds holding
Funds holding: 179 → 172 (-7)
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
Top Buyers
| 1 |
CAC
Cowen and Company
New York
|
+$66.9M |
| 2 |
Morgan Stanley
New York
|
+$47M |
| 3 |
State Street
Boston,
Massachusetts
|
+$33.5M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$20.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.6M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$152M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$39.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$14.4M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$12.9M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.2M |
PTCT Hedge Fund Activity: Q4 2023 in Review
172 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2023, worth a combined $2.37B — up 29% from $1.84B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PTCT and 26 opened new positions — a net loss of 4 holders — while 56 trimmed existing stakes and 71 added.
The largest buyer was Cowen and Company, adding an estimated $66.9M. The largest seller was Fidelity Investments, cutting an estimated $152M.
- 172 institutional investors held PTC Therapeutics (PTCT) as of Q4 2023, down from 179 in Q3 2023.
- Funds reported $2.37B of PTC Therapeutics stock for Q4 2023, up 29% quarter-over-quarter.
- 26 funds opened new PTC Therapeutics positions in Q4 2023 and 30 closed out, a net change of -4 holders.
- The largest PTC Therapeutics buyer in Q4 2023 was Cowen and Company, an estimated $66.9M added.
- The largest PTC Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $152M sold.
Based on aggregated 13F filings for Q4 2023.